CA-TERIDION
23.5.2019 14:02:12 CEST | Business Wire | Press release
Teridion , the company delivering the only global public cloud-based WAN service , today announced its deep integration with Cisco Meraki MX Security and SD-WAN appliances. The combined solution is a bold new approach to branch networking, delivering the industry-leading Auto VPN and SD-WAN capabilities of Cisco Meraki’s MX appliances with Teridion’s high throughput and low latency public cloud-based WAN service.
For the first time, enterprises can take advantage of a WAN solution that has visibility and control of first, middle, and last mile of the Internet and extends SD-WAN and WAN acceleration beyond enterprise sites to include SaaS applications and enterprise cloud workloads across multiple public cloud providers. Today’s announcement highlights the new, seamless network level integration between Teridion’s high performance cloud WAN service and Cisco Meraki’s easy-to-use Auto VPN routing and high availability capabilities. Enterprise of all sizes can expect real-time applications such as voice and video to see latency improvements of up to 30 percent and file transfer throughput increases of up to 500 percent. As always, the Cisco Meraki and Teridion solution is secured with Cisco’s market-leading security capabilities and managed in the cloud.
The Teridion cloud WAN service is a simple, snap-in integration with Cisco Meraki MX enterprise security and SD-WAN appliances that brings carrier grade Internet and WAN performance to broadband and dedicated Internet access connections. Teridion is available at a fraction of the cost of carrier circuits, and is backed with an SLA. Partners that offer the combined Cisco Meraki and Teridion solution will be able to engage more opportunities and offer a compelling new service to their installed base.
“This news is tremendous validation for the differentiated WAN offering we launched late last year,” said Pejman Roshan, VP of Products and Marketing for Teridion. “We have been working closely with Cisco Meraki on this deep integration, and together the combined solution makes it easy to deploy a secure and high performance WAN that is 100-percent cloud managed. Together, Cisco Meraki and Teridion enable businesses with regional, nationwide, or global WANs to drastically improve the performance of business critical applications, whether they are hosted in corporate data centers, SaaS applications, or deployed across various cloud providers.”
“As enterprises prepare for a cloud-ready application environment, they are laser focused on providing the best application performance for staff and customers in remote locations and branch offices,” said Raviv Levi, director of product management at Cisco Meraki. “The combined Cisco Meraki and Teridion solution offers rich SD-WAN and security capabilities at the WAN edge that are tightly integrated with a high performance and cost-effective WAN service delivered over cost-effective broadband or dedicated Internet access. This brings better reliability and consistency to the enterprise WAN across multiple sites, as well as high performance access to all SaaS applications and cloud workloads.”
Teridion also announced today the general availability of Teridion for Enterprise, the industry’s first solution that eliminates the reliability and performance gap introduced by the reliance on the public Internet middle-mile and exposed by the massive shifts to the cloud and SD-WAN. By tightly integrating with a leading SD-WAN solution such as the Cisco Meraki SD-WAN, Teridion unites centralized cloud management, enterprise-grade security, and ultra-fast WAN performance in a single, tightly integrated offering. As a result, enterprises leverage a solution that is optimized for delivery performance, reliability, control, and visibility end to end across the public Internet.
Teridion’s public cloud-based WAN service is powered by Teridion Curated Routing , an innovative and cloud native approach to routing that draws on the power of deep learning and brings hierarchical and centralized routing to enterprise networking. Teridion Curated Routing radically improves WAN, application, and SaaS performance. Originally launched delivering interoperability with today’s most popular SD-WAN offerings, today’s announcement marks the first deep, end-to-end integration with a leading SD-WAN solution.
Learn more about Teridion’s deep integration with Cisco Meraki in the Cisco Meraki Marketplace at https://apps.meraki.io/details/teridion-for-enterprise/ , or at teridion.com/meraki .
Availability and Pricing
Teridion for Cisco Meraki is available today from authorized Teridion resellers. Pricing starts at $50 per site per month. More details about how to buy can be found at https://www.teridion.com/meraki .
About Teridion
Founded in 2013, Teridion enables faster and more reliable Internet with Teridion Curated Routing, radically improving Internet performance up to 2X - 20X, anywhere in the world. Teridion for Enterprise combines the performance, reliability, and SLAs of legacy WAN technologies such as MPLS with the agility and elastic scalability of the cloud. The company is backed by leading venture investors including Jerusalem Venture Partners, Magma Venture Partners and Singtel Innov8, and is relied on by leading SaaS providers such as Atlassian, Box, Egnyte, Merrill Corp., and many others. Teridion is headquartered in San Francisco, with international offices in Petah Tikva, Israel. For more information, visit www.teridion.com or email info@teridion.com .
Teridion is a registered trademark of Teridion in the United States and other countries. All rights reserved. All other company and product names are either trademarks or registered trademarks of their respective companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190523005161/en/
Contact:
Dan Spalding dspalding@teridion.com (408) 960-9297
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom